Education
About Us
Working with TipRanks
Follow Us
PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
MDMA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.34
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.89K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)C$198.55K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
May 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding94,290,240
10 Day Avg. Volume200,320
30 Day Avg. Volume208,893
Standard Deviation0.54
R-Squared0.00805
Alpha0.13
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)49.90
Price to Cash Flow (P/CF)-17.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
PharmAla Biotech Holdings, Inc. News
PremiumCompany Announcements
PharmAla Ships LaNeo™ MDMA to UCLA for Schizophrenia Trial
PremiumCompany Announcements
PharmAla Advances MDMA Trial for Military PTSD Treatment
PremiumCompany Announcements
PharmAla Biotech Strengthens Advisory Team with New Agreement
PremiumCompany Announcements
PharmAla Partners with Israeli Center for Groundbreaking MDMA Trial
PremiumCompany Announcements
PharmAla Biotech Secures Data License, Settles Debt
PremiumCompany Announcements
PharmAla Biotech to Supply MDMA for Yale Trial
PremiumCompany Announcements
PharmAla Partners with University for Clinical Trial---
Options Prices
Currently, No data available
---
Ownership Overview
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.07 and its highest was C$0.34 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
Currently, no data Available
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is May 05, 2025 which is in 63 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 94,290,240 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
---
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions.
---
Technical Analysis
Numinus Wellness
―
Cybin
―
Red Light Holland
―
Psyched Wellness
―
HAVN Life Sciences
―
---